Huang, Zhuying
Kartos Therapeutics, Inc. (United States)
2 papers on CoChat
Most cited papers
- Verified
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed/Refractory Myelofibrosis
Mascarenhas, J. O., Popov, V. M., Mohan, S., Özkurt, Z. N., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Huang, Z., Qamoos, H., McGreivy, J., et al. (2024) · Blood
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 17
- Verified
Disease-modifying activity of navtemadlin correlates with clinical responses in a randomized, multicenter, global phase 3 study (BOREAS) in JAK-inhibitor relapsed/refractory myelofibrosis
Mascarenhas, J. O., Bose, P., Hou, H.-A., Homenda, W., Ross, D., Mohan, S. R., Kiladjian, J.-J., Al-Ali, H. K., Perkins, A., Khalina, Y., et al. (2024) · Blood
Myeloproliferative Neoplasms: Diagnosis and TreatmentAcute Myeloid Leukemia Research
Cited by 8
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free